ASCO® 2024 Review: Updates in the Management of Resectable Esophageal Adenocarcinoma

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ASCO® 2024 Review: Updates in the Management of Resectable Esophageal Adenocarcinoma

By Nebraska Oncology Society FEATURING Rachael Safyan

0 views

July 29, 2024

Comments 0

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser

ASCO® 2024 Summary: "Expert Panel Discussion on Upper-GI Cancer…

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini